The DNA base excision repair (BER) pathway repairs alkylation and oxidative DNA damage caused by endogenous and exogenous agents, including chemotherapeutic agents. Upon removal of the damaged base AP endonuclease 1 (Apel), a critical component of the pathway cleaves the abasic site to facilitate repair. Apel is a multifunctional protein which plays a role 11ot only u1 DNA repair but it also functions as a reduction-oxidation factor, known as Ref-1 in the literature, to increase the DNA binding ability of several transcription factors involved in different growth signaling pathways. Elevated levels of Apel have been linked to resistance to chemotherapy, poor prognosis, and poor survival. Reducing the amount of Apel protein in cancer cells and tumors using RNA interference and anti-sense oligonucleotide technology sensitizes mammalian tumor cells to a variety of laboratory and chemotherapeutic agents. Therefore, selective inhibition of Apel's DNA repair activity is a promising avenue to develop novel cancer therapeutics. Antioxid. Redox Signal. 11, 651-667.
Introduction
Importance of DNA repair pathways and cancer D NA REPAIR PATHWAYS PROTECT THE GENOME from damage caused by endogenous and exogenous DNA damaging agents, including chemotherapeutic agents and radiation damage (24, 44) ; the persistence of unrepaired DNA damage results in cell cycle arrest, apoptosis, and accumulation of mutations (47, 87) . To protect cellular DNA, several DNA repair pathways such as the Base Excision Repair (BER), Nucleotide Excision Repair (NER), Mismatch Repair (MMR), Homologous Recombination (HR), and Nonhomologous End Joining (NHEJ) exist in the cell to ensure temporal and efficient repair of a variety of damage (24, 44) . In addition, the importance of multiple DNA repair patl1ways is highlighted by several syndromes with a predisposition to cancer, which harbor germ line mutations in DNA repair genes. Currently, chemotherapy and radiation therapy are the mainstream treatment options available to treat cancers. Most of the chemotherapeutic drugs act by damaging DNA which leads to an accumulation of damage resulting in impaired cell signaling and ultimately causing cell death (56) . Normal cells are proficient in all forms of DNA repair; however, deficiency of a particular DNA repair pathway in cancer cells can lead to elevated levels of other DNA repair pathway proteins, leading to efficient repair of DNA damage and reducing the efficacy of cancer therapy. Cancer cells deficient in the proteins of the HR pathway, for instance, may be unable to repair damage efficiently through this pathway and may look to compensate for this deficiency by completing repair through alterna ti ve pathways such as the NHEJ or BER pathway (16, 76, 82) . The ability of cancer cells to identify and repair such DNA damage undermines the efficacy of these agents, and acquired or intrinsic cellular resistance to tl1ese clinical DNA-damaging agents is governed by the enhanced or elevated levels of DNA repair proteins (12, 31, 59, 90) . Although it may sound paradoxical to inhibit DNA repair pathvvay proteins since cancer promotion and deregulated cellular growth is aided by deficient DNA repair pathways, a fine balance exists between induction of DNA dan1age and its efficient repair that is often responsible for resistance to chemotherapy (12, 92) . Thus, inhibiting specific proteins from DNA repair pathways in cancer cells would provide us with a selective \.Vay to sensitize cancer cells to chemotherapeutic agents (90, 92) . Additionally, combining DNA repair inhibition with other current chemotherapy regimens (16) and thus developing targeted thera- (BER) pathway. The BER pathvvay is responsible for repairing damage induced by endogenous and exogenous agents, including chemotherapeutic agents. Repair is initiated by a damagespecific DNA glycosylase, that removes the damaged base to generate apurinic/apyrimidinic (AP) sites. AP sites can also be generated as a result of spontaneous base hydrolysis. Monofunctional DNA glycosylases remove the damaged base to generate an AP site, whereas bifunctional glycosylases in addition to excising the damaged base also nick the phospodiester backbone, 3' to the AP site. AP endonuclease 1 (Apel), a critical component of the BER pathway, then processes the AP sites by hydrolyzing the backbone 5' to the AP site to genera te 3'0H and 5'dRP groups. The 5' dRP group is removed by the dRPase function of DNA polymerase f3 and it also fills in the correct base. Repair is completed by DNA ligase III/XRCCl by sealing the nick. In the major short-patch (SP) BER pathway, regular AP sites are repaired by the removal of the single damaged base. Modified or oxidized AP sites are repaired by the long-patch (LP) BER pathway where a flap of 3-8 nucleotides is displaced and excised by Fenl. DNA polymerase {3, o, ore then inserts the correct nucleotides and repair is completed by sealing of the nick by DNA ligase l.
pies are generating robust interest. Here we describe the DNA Base Excision Repair (BER) pathvvay \Vith a focus on Apel as a targeted approach to cancer therapeutics.
DNA base excision repair (BER) pathway
The DNA base excision repair (BER) pathvvay repairs alkylation and oxidative damage caused by endogenous and exogenous agents, including radiation and chemotherapy-induced damage (24, 44). The BER pathway recognizes and repairs single base lesions including N-alkylated purines (N3-meth yladenine, N7-n1ethylguanine, and N3-meth ylguanine), 8-oxo-7,8-d ihydroguanine(8-0xoG), thymine glycols, 5-0H and 6-0H dihydrothymine, uracil glycol, 5-hydroxycytosine, and urea residues, in addition to a number of additional adducts (4, 24, 37) . Repair of the damaged base is initiated by a DNA glycosylase (Fig. 1 ) which specifically recognizes and excises the damaged base. Different DNA glycosylases recognize specific and different types of base damage. Glycosylases are of two types-monofunctional and bifunctional glycosylases. Monofunctional glycosylases [e.g., N-methyl purine DNA glycosylase (MPG)] excise the damaged base to generate an apurinic/apyrimidinic (AP) or abasic site. In contrast, bi functional glycosylases, in addition to exhibiting glycosylase activity, also have an AP lyase function (20, 27) . Bifunctional glycosylases such as 8-oxoguanine DNA glycosylase (OGGl), Nei endonuclease VII like, NEILl, NEIL2, and NTH not only excise the damaged base but also nick the phosphodiester backbone 3' to the AP site (24, 37). Removal of the damaged base by a DNA glycosylase creates an AP site, and AP sites are also generated by spontaneous base loss in the genome (29, 87).
The second critical component of the pathway is the multifunctional protein apurinic/ apyrimidinic endonuclease (Apel). Following hydrolysis by a DNA glycosylase, Apel processes the AP site by making an incision in the phosphodiester backbone immediately 5' to the AP site. This incision creates 3'0H and 5' deoxyribose phosphate (5'dRP) termini. At this stage, repair can proceed via one of two pathways (Fig. 1) . The short-patch BER (SP-BER) pathway repairs regular AP sites. Tn the short-pa tch path\·vay, DNA polymerase {3 (Pol {3) removes the 5'dRP moiety via its dRPase activity and uses the 3'0H terminus to insert the correct base. Subsequently, DNA ligase III/XRCCl (X-ray cross-species complin1enting 1) seals the nick and repair is completed. The long-patch BER (LP-BER) pathway preferentially repairs modified (oxidized, reduced) AP sites. In this minor BER pathway. a flap of three to eight nucleotides surrounding the AP site is displaced. The correct nucleotides are inserted by DNA polymerase /3, o, ors, along vvith proliferating cell nuclear antigen (PCNA) and replication factor-C (RF-C). Following resynthesis, flap endonuclease 1 (FENl) removes the displaced strand and then the nick is sealed by DNA Ligase Tor DNA Ligase TTI/XRCCl (37). Oxidative DNA lesions can also be excised by the recently identified Neil glycosylases NEILl and NEIL2 that shov.r homology to the E. coli endonuclease VIII (5, 53-55, 69, 122) . The AP sites generated are processed by Apel and subsequent repair is completed. While there are several different DNA glycosylases to excise the damaged base and generate AP sites, there is only one
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Apel protein, which can process the AP sites generated and facilitate repair, thus emphasizing its significance in the BER pathway.
The Ape1 protein, an essential component of the BER pathway
Based on the method of incision, AP endonucleases can be classified into two classes. The Class I AP endonucleases are also known as AP lyases (or {3-lyases) as they process the AP sites by the ,B-elimination reaction and cleave the phosphodiester backbone 3' to the AP site, generating a 5' phosphate and a 3' a,{3-unsa turated aldehyde end. This AP lyase activity is usually associated w ith complex DNA glycosylases which are responsible for repairing oxidatively damaged DNA (27). The Escherichia coli endonuclease 111 and endonuclease Vlll (52) a nd the human homologue NTHl (57, 58, 64) belong to this class of endonucleases. Class II AP endonucleases are the major class of endonucleases and are also known as hydrolytic endonucleases, as they hydrolyze the phosphodiester backbone 5' to the AP site, creating normal 3'0H and 5' deoxyribose phosphate termini. Based on homology, Class TT AP endonucleases can be further classified into two families, the exonuclease III (xth) and the endonuclease lV (nfo) family. The exonuclease III family consists of human Apel in addition to enzymes from various phyla, and these enzymes possess a strong AP endonuclease activity (29, 37, 110, 119, 133) . In addition to the endonuclease activity, Apel also possesses a 3' -repair diesterase activity. Although this 3'-repair diesterase activity is much weaker (almost 200-fold weaker) (20) than the AP endonuclease activity, it is important in the removal of 3' blocking lesions such as phosphoglycolate moieties in order to complete repair (20, 37, 42, 104) . ln the BER pathway, Apel is responsible for p rocessing AP sites generated as a result of the action o f both types of DNA glycosylases (29, 32, 117) . This processing of AP sites by Apel then faci litates complete repair of the damaged base. The endonuclease IV family of enzymes is the second major family of Class I.I AP endonucleases which include the£. coli endonuclease IV and Apnl from Saccharomyces cerevisine (yeast) which is responsible for 90°/o of AP endonuclease activity in S. cerevisiae (37, 73, 108, 128) . Apnl can repair both alkylation and oxidative damage, including oxidized abasic sites and unlike Apel, Apnl has a higher 3' repair-diesterase activity (43) . Although the enzymes from both families share the AP endonuclease function, they do not share sequence or structural simi larity (29, 99).
Functions of Ape1
The AP endonuclease activity of Ape 1
Apel is responsible for 95o/o of the endonuclease activity in the cell and is a critical part of both the short-patch and the long-patch BER pathway (29, 32, 11 7). Recognition of the damaged base by a monofunctional DNA glycosylase and its s ubsequent removal genera tes an AP site. This AP site is recognized by Apel that hydrolyzes the phosphodiester backbone 5' to the AP site, generating a 3'0H and a 5' deoxyribose phosphate (5' dRP) terminus. Subsequently, regular AP sites are repaired via the SP BER path\-vay whereby the 5' dRP moiety is removed by the dRPase function of Apel (5, (53) (54) (55) 122) . Thus, Apel is functionally involved in the short-patch and long-patch BER pathv.rays. As discussed above, Apel has a strong 5' AP endonuclease activity, in addition to which it also has a 3'-repair diesterase activity which is important for the removal of 3' blocking lesions generated as a result of the ,B-lyase function of DNA glycosylases involved in the repa ir of oxidative or radiation-ind uced DNA damage (20, 37, 42, 104) . Blocking lesions such as 3'-phosphate groups and 3'-phosphoglycolate moieties generated by the action of oxidative agents s uch a bleomycin, radiation (IR), and also formed at sing le-strand breaks are removed by Apel's 3' -phosdiesterase function so that the subsequent steps of BER can take place and repair can be completed (19, 20, 99, 104, 124) . ln addition to its hydrolytic and 3' -diesterase functions, Apel also has a 3'-5' exonuclease activity which is important to process 3' mispaired termini (22) and for the removal of unnatural nucleoside analogs (21, 23) .
AP sites formed as a result of the action of D IA glycosylases can also be generated by spontaneous base hydrolysis in the cell (100), and Apel is required to further process these AP sites in order to complete repair. If left uruepaired, these AP sites can be cytotoxic and mutagenic as they can block the replicating polymerase (87, 132, 141) . Thus, although AP sites can be generated by the action of several different damage specific DNA g lycosylases, only Apel can process these AP sites and facilitate repair, thus emphasizing its significance in the BER pathway. Furthermore, importance of Apel to normal cellular fun ctioning is highlighted by the embryonic lethality of Apel knockout mice (80, 138) . Elevated levels of Apel in cancer cells have been postulated to be areason for chemotherapeutic resistance (15, 37, 75, 77, 109, 114, 121, 130) and inhibition of Ape1 has been shown to increase cell killing and apoptosis and also sensitize cancer cells to chemotherapeutic agents. Lnhibition of Apel using DNA antisense and RNA interference technology is known to increase cell killing and apoptosis and also sensitize cancer cells to chemotherapeutic agents (14, 81, 102, 129) . These findings demonstrate the uniqueness of Apel as a molecular target in therapeutics.
Other repair functions of Ape 1
The multifunctional Apel protein has several other functions accompanyi ng its DNA repair and redox regulatory activities. As part of its DNA repair activity, Apel removes 3' blocking lesions generated by DNA glycosylases v.rhich recognize oxidative damage (Oggl, Neil} (33, 37, 54) via its 3'-phosphodiesterase and 3' -phosphatase activities to facilitate complete repa ir. Apel also possesses a 3'-5' exonuclease ac-tivity which is important for the removal of deoxyribonucleoside analogs which can impede repair (19, 22, 23, 34) . In addition to the afore mentioned functions, Apel has been shown to inhibit the activation of PARPl (poly(ADP-ribose)polymerase 1) during oxidative damage repair, thus preventing the cells from undergoing apoptosis (105) . A relationship between Bcl2 and Apel resulting in decreased repair has been reported (72) in addition to negatively regulating the parathyroid hormone gene (PTH) (13, 25, 78, 101) , being involved in granzyme A (GzmA) aided NK cell-mediated killing (39, 93) and it has been implicated in nucleotide incision repair (NIR) (65, 66) . Apel has also been suggested to play a role in negatively regulating the Rael/ GTPase to prevent oxidative stress (103) and to regulate vascular tone and endothelial NO production (71) (Fig. 2) .
The redox function of Ape 1
In addition to the AP endonuclease function of Apel, it also functions as a reduction/oxidation (redox) signaling factor ( Fig. 3 ) and is therefore also referred to as Redox effector factor-1 (Ref-1) in the literature (1, 2, 135, 136) . Ref-1 reduces key cysteine residues located in the DNA binding domains of transcription factors such as APl (Fos/Jun), p53, HIF-la, and others (3, 36, 48, 62, 63, 79, 96, 125, 126, 135, 136, 140) . This reduction of the critical cysteines in the DNA binding domains of the transcription factors increases their DNA binding ability. Increased DNA binding ability of these transcription factors activates them which leads to the transcription of several key genes important for cell survival and in cancer promotion and progression (37, 124). Thus, the multifunctional Apel protein not only functions in and interacts with the proteins involved in the repair of damaged DNA, it also interacts with proteins involved in growth signaling path,~rays and path~rays known to be involved in tumor promotion and progression. The redox function of Apel as a target in cancer has not been as extensively investigated as the DNA repair function of Apel. However, given its role in activating transcription factors such as NFKB, AP-1, and HIF-1a etc, inhibiting the redox ability of Apel should lead to decreased signaling via these transcription factors of the signaling pathways involved in cancer promotion and progression.
The repair and redox functions of Ape 1 are distinct from each other
As discussed previously, Apel is a multifunctional protein with roles in DNA repair as well as in redox signaling
in the cell. These two important functions of Apel are functionally distinct from each other and are encoded by distinct regions of the protein (137) . The AP endonuclease or DNA repair activity which is a c1itical component of the BER pathway resides in the C-terminal portion of the protein. The AP endonuclease activity is mediated by the active site residues His 309, Glu 96, Asp 238, and Asp 308, where H309 is the catalyt ic residue (6-8, 11, 37, 45, 50, 88, 98) . The redox regulatory activity of Apel which is important for the control transcription factors resides in the N-terminal sequences of the protein and a conserved Cys 65 residue is crucial for this function of Apel (9, 35, 37, 45) . These t\.vo important functions of Apel can be functionally separated from each other, and disruption of one of its activities does not affect the other. Several reports have shovvn that disruption of Cys 65 by sitedirected mutagenesis (21, 35) or by using a redox specific inhibitor, impairs the redox function of Apel but does not affect its DNA repair ability (112, 143) .
Apel is ubiqui tously expressed and though there are several reports sho~ring that Apel is localized to the nucleus, cytoplasmic localization of Apel has also been reported (34, 74, 97, 113, 134) . In addition to exhibiting a heterogeneous and complex pattern of staining, localization of Apel is tissue specific and even differs bet\~reen neighboring cells (113, 134) . Localization of Apel in the cytoplasm may be associated ~rith its role as a mitochondrial DNA repair protein (37, 97, 124) . Noting Apel's role in redox control of transcription factors, presence of Apel in the cytoplasm may be important to maintain these transcription factors in a reduced state prior to their transport to the nucleus (34). Apel has also been shown to accumulate in the nucleus and mitochondria in response to DNA damage (97) . Thus, it appears that the intracellular localization of Apel is regulated; however the significance of its subcellular localization is still not well understood.
Inhibition of DNA Repair as a Target in Cancer
DNA repair pathways are important to maintain the genomic integrity as highlighted by several cancer predisposing syndromes which harbor gerrnline mutations in DNA repair genes (24, 44, 59). Currently, chemotherapy and radiation therapy are the mainstream treatment options available to trea t cancers. The cytotoxic effects of most chemotherapeutic agents and radiation are rela ted to their ability to induce DNA damage. The ability of cancer cells to identify and efficiently repair such DNA damage undermines the ef-FIG. 2. The complex n etw ork of protein-protein interactions of Apel . Apel is a multifunctional protein with a role in DNA repair to maintain genomic integrity and a function in cellular redox signaling to activate key transcription factors, leading to changes in expression of genes involved in crucial cellular processes. In addition to these functions, Apel interacts \.vith several different proteins from the BER path\.vay and other DNA repair and signaling pathways to create a complex mesh of direct and indirect interactions. This matrix is a graphical representation of the molecular relationships between genes or gene products (proteins or complexes). Each gene or protein is represented as a node and the lines (edges) joining them represent the biological relationships beh-veen them. At least one reference from the literature, from a textbook, or from canonical information stored in the Ingenuity knowledge base corroborates each edge. Orthologs of a gene (human, mouse, and rat) are represented as a single node in the network but are stored as separate objects in the Ingenuity knowledge base. The various shapes of the nodes represent the functional class of tha t gene product. The nature of an edge is descripti ve of the nature of the relationship between the nodes (e.g., solid line indicates a direct relationship, dashed line indicates an indirect relationship, etc). This interaction network \~ras generated through the use of Ingenuity Pathways Analysis (Ingenuity Systems®, www.ingenuity.com). (For interpretation of the references to color in this figure legend, the reader is referred to the ~reb version of this article at www.liebertonline.com/ars). ficacy of these agents (111, 127) . Therefore, inhibiting DNA repair proteins leading to reduced repair of damaged DNA in cancer cells is an attractive approach to combat chemotherapeutic resistance and to increase efficacy of therapy. Although it may sound contradictory to inhibit DNA repair pathway proteins, since cancer promotion and deregulated cellular growth is aided by deficient DNA repair pathways, it actually makes sense to block DNA repair, given the predominance of DNA damage during cancer treatments with chemotherapy and IR, which would allo'~' for increased efficacy of the DNA damaging agent (12, 92) . Thus, inhibiting specific proteins from selected DNA repair path~rays in cancer cells could provide us \Vith a selective way to sensitize cancer cells to chemotherapeutic agents and also combat their resistance to chemotherapeutic agents (90, 92) .
Consequences of inhibiting the BER pathway in cancer
The BER pathway is responsible for repairing DNA damaged by endogenous and exogenous agenl'> including chemotherapeutic agents. In addition to repairing damaged lesions, the proteins of the BER path~ray exhibit several important protein-protein and DNA-protein interactions (38) and a delicate balance exists between the levels of all the BER proteins (49) . In cancer cells, the upregulation of the BER proteins results in imbalanced repair and can lead to resistance to chemotherapeutic agents; modulating or inhibiting the activities of these BER proteins can lead to deregulated repair, resulting in sensitivity to chemotherapy agents. Ho,-vever, tl1e central idea that presence of robust DNA repair mechanisms leads to resistance to chemotherapeutic agents (12, 26, 31, 56, 82, 92, 120) has been challenged by some studies. Roth et al. {116) showed that absence of Aag (3MeA DNA glycosylase) in the bone marrow (BM) cells of the myeloid lineage from Aag -/-mice are resistant to alkylating agents (MMS), as compared to the wild-type BM cells. They speculated that initiation of repair by Aag and subsequent incomplete repair of the lesions in ~rild-type BM cells may be more toxic than the inability of Aag null BM cells to initiate repair of these damaged lesions. This effect was specific to the myeloid lineage of the Aag -/-mice and was not observed in embryonic stem cells (ES), primary embryonic fibroblasts (PEF) and cells from the lymphoid lineage in the BM, indicating that this effect is tissue specific, as \-vell as likely lesion specific. In general, it has been shown that presence of DNA repai r contributes to resistance to chemotherapeutic agents. DNA glycosylases show quite a bit of functional redundancy (80) , and the action of all the DNA glycosylases results in the formation of AP sites. For instance, overexpression of 3MeA DNA glycosylases in S. cerevisiae and E. coli leads to increased sensithrity to alkylating agents and spontaneous mutations, possibly due to an imbalance between the levels of the DNA glycosylase and Apel proteins and also due to the build-up of unrepaired AP sites (116) . Accumulation of these unrepaired AP sites can lead to (Fig. 4) singlestrand breaks, increased apoptosis, and enhanced cytotoxicity (47) . Apel is required to process these AP sites and along with the rest of the BER proteins can facilitate the ensuing completion of repair. Increased expression of the BER pathway proteins in cancer cells can result in efficient repair of damaged lesions and can reduce the effecti veness of chemotherapeutic agents. Therefore, keeping in mjnd the importance of the BER path way in the repair of damage induced by chemotherapy, exploiting the BER pathway and its proteins by inhibiting them would increase the efficacy of chemotherapy, thus making it an attractive target to develop novel means in order to combat chemotherapeutic resistance (120) .
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Inhibition of the DNA Repair Function of Ape1 as a Rational Cancer Target
There are several reasons why Apel is a rational target for chemotherapeutic agents: (a) overexpression of Apel leads to chemoresistance; (b) strated that the redox fun ction of Apel is important in hematopoietic differentiation (growth) by using a specifi c inhibitor of Apel's redox activity, but did not cause the cells to undergo apoptosis (143). These observations not only suggest a crucial role for both of Ape l's functions in cellular survival and tumor promotion and progression, but also demonstrate differences observed '~'hen the redox or repair functions are blocked. Developing specific inhibitors of the two functions of Apel v.rould further allow us to discern which of the activities of Apel are important for cancer promotion and progression and normal cellular survival. Furthermore, the two functions may play different roles in different kinds of cancer, allowing us to better understand tumor progression. Thus, the consequences of inhibiting of Apel in cancer cells point to it being a logi.ca l target in cancer therapeutics. Identification of molecules that specifically inhibit Ape l's repair or redox activity should be an effective means to sensitize cancer cells to chemotherapeutic agents and thus impact the development of new and targeted cancer therapies. This reviev.r will focus on repair inhibition (see review for information on redox inhibitors) (42) .
Existing Ape1 DNA Repair Inhibitors
As discussed above, Apel's importance in the BER pathway and unique role supports the hypothesis that it is a strong target for cancer therapy; elevated levels in cancer cells and knocking down Apel using siRNA leads to increased ability of cancer cells to undergo apoptosis and sensitization to chemotherapeutic agents (14, 37, 75, 77, 109, 114, 121, 130) . Thus, combining standard chemoth erapeutic strategies with targeted inhibitors of Apel's DNA repair function ,~rould increase the effectiveness of existing chemotherapeutic regimens. Currently three compounds are kno'~'n to inhibit Apel's DNA repair activity, methoxyamine (MX) and two compounds, CRT0044876 or 7-nitroindole-2-carboxylic acid (NCA) (91) , and an arylstibonic acid compound (118), both identified in high throughput screening (HTS) assays.
Methoxyamine (MX), an indirect inhibitor of Ape1's repair activity
Methoxyamine (MX) is an inhibitor of Apel vvhich interacts with the aldehydic Cl atom left at the DNA abasic site after removal of the damaged base by a DNA glycosylase (86) . tvfX is considered to be an indirect inhibitor of Apel in that it does not directly bind to Apel and inhibit its activity.
Ra ther, MX binds to AP sites and prevents Apel and Pol f3 from processing them further and completing repair. As a single agent, MX is not significantly cytotoxic, however MX can potentiate the cytotoxicity of alkylating agents such as TMZ and l,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) (41, 84, 123) . TMZ predominantly alkylates guanine at the N7 and 06 positions and adenine at the N3 position. The BER pathway repairs N7 and N3 alkylation damage and the ac- Clinical trials with MX in combination w. ith TMZ are currently being p ursued. A direct repair inhibitor with the ability to directly block Apel's repair activity should prove to be more potent in sensitizing cells to chemotherapeutic alkylating agents while reducing nonspecific effects. As discussed previously, MX is currently in use to block Apel's ability to repair AP sites. Ho"\>vever, this reagent targets the DNA (AP sites) and not Apel directly (86, 115) . tvlX stably interacts vvith the Cl' aldehyde atom resulting from the removal of the damaged base, producing a stable covalent adduct (86); Apel is unable to readily <leave the resulting MX-AP site (46) . MX is a simple compound, H 3 CONH 2 , with no obvious potential for improvement in efficacy through derivatization and high concentrations of MX are required in cell-based assays (20-50 mM) in order to potentiate cell killing in combination \.Vith other agents (85, 94, 123, 139) . In addition, since MX binds AP sites and not Apel directly, it will also affect the ability of other mammalian enzymes to bind DNA substrates including DNA Pol /3 (61) .
Lucanthone, a direct inhibitor of Ape 1 's repair activity
Lucanthone, originally identified as a topoisomerase II poison (10) , is considered to be a direct inhibitor of Apel's DNA repair activity. Its extensive use to treat schistosomiasis has shown it to be safe and nearly nontoxic from a clinical standpoint (28). Cancer cells treated with lucanthone exhibited a dose-dependent increase in AP sites, seemingly due to inhibition of Apel's repair activity and blocking an early step in the BER pathway (95) . Pa tients \.vi th brain metastasis treated in combination with radiation and lucanthone showed increased regression of the tumors with the combination, as compared to radiation alone (28). Additionally, lucanthone enhances the cell killing effect of MMS and TMZ in breast cancer cells by the inlubition of Ape l's DNA repair activity (89) . However, the evidence of lucanthone, also being a topoisomerase 11 inhibitor, raises the concern that the tumor cell killing observed could be partially attributed to the off-target effects of lucanthone, vvhich again points to the need of a robust direct inhibitor of Apel's repair function.
7-Nitroindole-2-carboxylic acid (NGA), a direct inhibitor of Ape 1 's repair activity
Madhusudhan et al. (91) identified CRT0044876 or 7-nitroindole-2-carboxylic acid (NCA) in a high-throughput screen (HTS) of a library of 5,000 drug-like compounds to be a direct inhibitor of Apel's repair activity with an IC 5 o value of -3 µM. NCA is negati vely charged and is reported to inhibit all the DNA repair activities of Apel such as the AP endonuclease (repair activity), 3' -p hosphodiesterase, 3'-5' exonuclease, and 3' -phosphatase activities of Apel. Survival analyses in HT1080 human fibrosarcoma cells showed that NCA potentiates the cytotoxicity of MMS, TMZ, H 2 0 2 , and zeocin (91) . rlowever, efforts to reproduce this repair inhibition have not been realized by our laboratory and by others (51) (Fig. SA and B) . FIG. 7. Scatter plot for the Z' factor 1neasure1nent. This is a sca tter plot of the positive and negative con trol data for Apel HTS assay. The Z' factor for the assay was calculated from the formula described by Zhang et al. (141) . The Z' factor calculated for this assay is 0.78.
Arylstibonic acid compounds as inhibitors of Ape 1 's repair activity
Recently, Seiple et al. (118) screened an NCI Diversity Set library of 2,000 compounds to identify specific inhibitors of Apel. The authors identified an arylstibonic acid co1npound 13755 which has a negative cl:iarge, as an inhibitor of Apel's DNA repair activity. This compound shows partial mixed type inhibition in that it binds both to the enzyme and the enzyme substrate complex. Even though these compounds have been reported to inhibit Apel's DNA repair activity in vitro, they have virtually no cellular uptake and are less attractive as translational agents. Treatment of 1-IOS osteosarcoma cells with 5 µM of the compound in the presence of MMS did not shov.r decreased survival in cytotoxicity assays (118) .
Need for Specific Inhibitors of Ape1 's DNA Repair Activity
There is a clear need for a specific repair inhibitor of Apel in order to effectively determine the role of Apel's repair activity in potentiating the effects of alkylating cl1emothera· peutic agents. This is required given the importance of in· hibiting Apel using siRNA leading to sensitization of cancer cells to chemotherapeutic agents (14, 15, 75, 81, 87, 114, 121, 129, 130) . However, these studies remove all of Ape l's functions (repair and redox) as well as Apel's protein-protein interactions (38), making the data difficult to interpret. Thus, identifying specific and potent Apel repair inhibitors would facilitate the understanding of Apel not only in cancer, but also in dividing normal cells (bone marrov.r, gut, etc), nondividing normal cells (neurons), and other diseases where Apel has been implicated {17, 47, 60, 67, 106, 124) . In addition, these small molecule inhibitors will allow the specific inhibition of Apel's repair function v.rhile keeping its post· translational modifications (18, 68, 70, 97) and subcellular location of Apel intact and in determining the effect of blocking Apel's function on these subcellular events (30, 107, 124) . In summary, identification of specific inhibitors of Apel's repair activity \-vill further our ability to determine the role it plays in cancer promotion and progression, thus making a productive target of chemoprevention.
High Throughput Screening (HTS) Methodology to Identify Specific Inhibitors of Ape1 's DNA Repair Activity
High throughput screening (HTS) is an efficient scientific method that allows the assay o f large numbers of varied chemical compounds against biological targets in a rela tively short period of time. HTS assays are either entirely or partially automated and can be carried out in the 96-well or 384-well forma t. Robotic automation in HTS helps speed up the process of drug discovery and facilitates the generation of a large amount of scientific data in a short time-frame. Several different libraries of synthetic and drug-like compounds are available for HTS. Typically, the first round of HTS is car· ried out ,~rith a fixed concentration (1-10 µM) of the cherni· cal compound. The positive 'luts' identified in the pri1nary assay can be re-screened in the same assay and these hits are then followed up in secondary assays to validate them, determine an TC 50 concentration, and perform functional cellular assays. Thus, HTS is a promising and rapid methodol- ogy to identify potential modulators of the biological activity of the target from a large number of compounds.
Efforts are under way in our laboratory to identify and develop a novel inhibitor of Apel's DNA repair activity using the HTS methodology. We have modified the fluorescencebased high throughput screening assay described by Madhusudhan et al. (91) to screen a library of 60,000 synthetic drug-like compounds \.Yhich follow Lipinsky's rule of five (83) from Chemical Diversity Ltd Inc. (San Diego, CA). We used purified Apel protein at a concentration that showed a linear range for the assay over a period of time (Fig. 6) . 1n order to determine the reliability of the assay, we performed control experiments and calculated the Z'-factor score of0.78 (Fig. 7) . The Z' -factor reflects the dynamic range between the positive and negative controls and is also a reflection of the reproducibility of the data and reliability of the assay. The Z'-factor values range from 0.5 to 1.0, and a score above 0.5 is an indication of a good assay, \.Yith 1 being a perfect assay (142). After an initial screen of the 60,000 compound library, we identified 190 compounds showing > 50°/ o inhibition of Apel's DNA repair activity. Of the 190 con1pounds, 174 \.Vere available and re-screened in the same HTS assay. Forty-five compounds showing 2::40°/o inhibition of Apel's repair activity were identified after two rounds of HTS screening. These 45 compounds are now being further validated in a secondary gel-based AP endonuclease assay to further assess inhibition of the compounds. On completion of the validation of the 45 compounds in the secondary assays, promising compounds will then be tested for their ability to specifically inhibit Apel's DNA repair ability in in vitro cellular assays, including cell growth, cytotoxicity, and apoptosis assays.
Jn the secondary gel-based AP endonuclease assay, a concentration of Apel protein in the linear range was titrated against a range of concentrations of the compounds. As a control, all the compounds tested in the gel-based AP endonuclease assay are compared to NCA, a known inhibitor of Apel's DNA repair activity, at a concentration of 10 µM (91) . One of the compounds identified in the HTS screen, AB-01, demonstrated consistent inhibition of Apel's DNA repair activity both in the HTS and the secondary gel-based AP endonuclease assay. As seen in Fig. 8A and B, compound AB-01 is able to inhibit Apel's DNA repair activity. At a concentra tion of 10 µM, inhibition o f Apel's DNA repair activity by AB-01 is better than that den1onstrated by NCA at the same concentration.
Conclusions
Ability of cancer cells to recognize and repair chemotherapy-induced damage is an important factor in resistance to chemotherapy (90) . Therefore, inhibiting DNA damage repair pathways and using inhibitors against specific proteins of these pathways is an excellent strategy to develop targeted therapies for cancer treatment. (12, 31, 59, 90, 92) . Apel is a an essential protein functioning in the BER pathway which repairs damage caused by endogenous as well as exogenous DNA base damage including chemotherapy-induced DNA damage (24, 37, 44). Apel is unique such that it is the only cellular protein that can process the AP sites generated as a result of the action of the DNA glycosylases. It is also the only DNA repair and redox protein in the cells and there is no backup for the critically important repair function of Apel in cancer cells. This makes it a unique target, particularly since it has tvvo important functions that work independently of one another. In addition to its important role in normal cellular functioning, altered or elevated levels of Apel have been observed in a variety of cancers, including breast cancer, gliomas, sarcomas (osteosarcomas, rhabdomyosarcomas), ovarian and multiple myeloma, among others (37, 75, 77, 109, 114, 121, 130) which have been speculated to be a cause of resistance to chemotherapy. In addition, these heightened levels of Apel have been linked to tumor promotion, progression, and poor prognosis associated with shorter relapse-free survival and poor outcome from chemotherapy (77) . There is a vast amount of data shov.ring that downregulating or inhibiting Apel in cancer cells using RNA interference and DNA antisense oligonucleotide techniques can sensitize them to laboratory and clinical chemotherapeutic agents (14, 15, 75, 81, 114, 121, 129, 131) . Since Apel is involved in the repair of DNA damaged by chemotherapeutic agents, identifying selective inhibitors of the DNA repair or redox activities of Apel would make it an excellent target, both from a single agent approach and in combination with chemotherapy and IR. Additionally, it may be coupled v.rith other specific molecular targets in cell cycle or other pathways to thwart the cancer cell from skirting cell death and prevent drug resistance from occurring. 
